Trial · NCT01287520
Results by group78
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 78
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD]) | LY2090314/Pemetrexed/Carboplatin | 40 | milligrams (mg) | ||
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2) | 216 | Geometric Coefficient of Variation 26.3 | nanograms*hour per milliliter | |
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 20/Carb 6/Pem 500 (Cohort 3) | 427 | Geometric Coefficient of Variation 21.8 | nanograms*hour per milliliter | |
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) | 976 | Geometric Coefficient of Variation 42.6 | nanograms*hour per milliliter | |
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) | 1870 | Geometric Coefficient of Variation 76.7 | nanograms*hour per milliliter | |
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 120/Carb 6/Pem 500 (Cohort 6) | 3310 | Geometric Coefficient of Variation 18.7 | nanograms*hour per milliliter | |
| Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314 | LY 60/Carb 6/Pem 500 + R50 (Cohort 8) | 1600 | Geometric Coefficient of Variation 47.3 | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2) | 192 | Geometric Coefficient of Variation 48.2 | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 20/Carb 6/Pem 500 (Cohort 3) | 404 | Geometric Coefficient of Variation 33.2 | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 40/Carb 6/Pem 500 (Cohorts 4 and 9) | 938 | Geometric Coefficient of Variation 33.5 | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 80/Carb 6/Pem 500 (Cohorts 5 and 7) | 1830 | Geometric Coefficient of Variation 7.84 | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 120/Carb 6/Pem 500 (Cohort 6) | 2190 | Geometric Coefficient of Variation NA | nanograms*hour per milliliter | |
| PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 60/Carb 6/Pem 500 + R50 (Cohort 8) | 1570 | Geometric Coefficient of Variation 36.5 | nanograms*hour per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2) | 122 | Geometric Coefficient of Variation 21.5 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 20/Carb 6/Pem 500 (Cohort 3) | 246 | Geometric Coefficient of Variation 29.0 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 40/Carb 6/Pem 500 (Cohorts 4 and 9 ) | 603 | Geometric Coefficient of Variation 47.7 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 80/Carb 6/Pem 500 (Cohorts 5 and 7 | 898 | Geometric Coefficient of Variation 50.5 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 120/Carb 6/Pem 500 (Cohort 6) | 1700 | Geometric Coefficient of Variation 63.2 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 | LY 60/Carb 6/Pem 500 + R50 (Cohort 8) | 881 | Geometric Coefficient of Variation 53.3 | nanograms per milliliter | |
| PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb) | LY 10/Carb 5 or Carb 6/Pem 500 (Cohorts 1 and 2) | 106 | Geometric Coefficient of Variation 57.5 | nanograms per milliliter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01287520/results